PERSPECTA

News from every angle

← Back to headlines

Teva Pharmaceutical Bids $57.5M for BioXcel Agitation Treatment Asset

Teva has submitted a $57.5 million bid to acquire an agitation treatment asset from BioXcel Therapeutics, marking a strategic move in its specialty portfolio.

28 Aug, 10:20 — 28 Aug, 10:20
PostShare

Sources

Showing 1 of 1 sources
investing-com1d ago

Teva bids $57.5M for BioXcel’s agitation treatment asset

By Investing.com

Read full article →

Related Stories

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

1h ago

Fed Chair Warsh Warns of Potential Rate Hikes Amid Stubborn Inflation

1h ago

Temasek Backs Singapore Airlines’ Strategic Investment in Air India

2h ago

Meta Agrees to $18 Billion Settlement Over Teen Safety Lawsuit

2h ago